Department of Medicine, Combined Miliary Hospital Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Department of Nephrology, Combined Miliary Hospital Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan.
J Vasc Access. 2024 Jul;25(4):1081-1086. doi: 10.1177/11297298221142375. Epub 2022 Dec 27.
Pain is a traumatic experience for most patients on hemodialysis. In this trial, we compared prilocaine/lidocaine cream with piroxicam gel for pain reduction during arteriovenous fistula needling.
This randomized double-blind crossover clinical trial was done at dialysis unit of a tertiary care hospital from June to August 2022. Adult patients, aged 18-75 years, on maintenance hemodialysis through an arteriovenous fistula were selected randomly. Pain severity during needling of fistula was assessed during initial two hemodialysis sessions without application of any drug. Patients were then randomized into two groups receiving 5% prilocaine/lidocaine cream or 0.5% piroxicam gel 1 h before the next two hemodialysis sessions. After a 7-day washout period, patients crossed over to other groups for another two hemodialysis sessions. Pain was assessed on all these occasions. Primary outcome was reduction in pain with each intervention.
There were 32 patients aged 46.44 ± 11.58 years. Pain intensity was 6.69 ± 0.58, 3.13 ± 1.28, and 4.55 ± 1.95 without any medication, prilocaine/lidocaine cream and piroxicam gel respectively. There was greater pain reduction with prilocaine/lidocaine cream than piroxicam gel (3.56 ± 1.35 vs 2.14 ± 1.78; = 0.001). Local redness with prilocaine/lidocaine cream was reported by one (3.13%) patient, whereas no side effects were seen with piroxicam gel ( = 1.000).
Prilocaine/lidocaine cream provides better pain relief than piroxicam gel during arteriovenous fistula needling.
疼痛是大多数血液透析患者的创伤性体验。在这项试验中,我们比较了丙胺卡因/利多卡因乳膏和吡罗昔康凝胶在动静脉瘘穿刺时减轻疼痛的效果。
这是一项于 2022 年 6 月至 8 月在一家三级医院的透析单元进行的随机、双盲、交叉临床试验。选择年龄在 18-75 岁之间、通过动静脉瘘接受维持性血液透析的成年患者。在没有使用任何药物的情况下,在最初的两次血液透析过程中评估瘘管穿刺时的疼痛严重程度。然后,患者被随机分为两组,分别在接下来的两次血液透析前 1 小时使用 5%丙胺卡因/利多卡因乳膏或 0.5%吡罗昔康凝胶。在 7 天的洗脱期后,患者交叉到另一组进行另外两次血液透析。所有这些情况下均评估疼痛。主要结局是每种干预措施的疼痛减轻程度。
共有 32 名年龄为 46.44±11.58 岁的患者。无任何药物、丙胺卡因/利多卡因乳膏和吡罗昔康凝胶时的疼痛强度分别为 6.69±0.58、3.13±1.28 和 4.55±1.95。与吡罗昔康凝胶相比,丙胺卡因/利多卡因乳膏可减轻更大程度的疼痛(3.56±1.35 对 2.14±1.78; = 0.001)。一名(3.13%)患者报告使用丙胺卡因/利多卡因乳膏后出现局部发红,而使用吡罗昔康凝胶时未出现任何副作用( = 1.000)。
与吡罗昔康凝胶相比,丙胺卡因/利多卡因乳膏在动静脉瘘穿刺时提供更好的疼痛缓解效果。